Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06)

Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06)

BackgroundNeoadjuvant chemoradiotherapy has become the standard treatment for mid-to-low location LARC. Recently, total neoadjuvant therapy (TNT) has been used in patients with ‘high-risk’ or ‘very high-risk’ LARC according to ESMO guideline (2017). TNT not only increases the pathological complete r...

Full description

Saved in:
Bibliographic Details
Main Authors: Meichen Gu, Yuchen Guo, Liang He, Xuan Sun, Tingting Liang, Zhuo Wang, Ying Li, Zheng Liu, Jingyu Wang, Xiang Qiu, Liang Guo, Pengyu Chang, Quan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
locally advanced rectal cancer
total neoadjuvant therapy
immunotherapy
immune checkpoint inhibitor
pathological complete response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1594927/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1594927/full

Similar Items